URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$33.48
−0.80%Forward multiples
Based on analyst estimates
- P/E forward
- 16.24x
- P/E 2026E
- —
- P/E 2027E
- 12.03x
- P/E 2028E
- 6.90x
- P/S forward
- 3.39x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -12.36x
- Price / sales
- 8.67x
- Price / cash flow
- -10.30x
Enterprise value
- Enterprise value
- $1.7B
- EV / sales
- 9.14x
- EV / EBITDA
- -24.59x
- EV / EBIT
- -25.88x
- Market cap
- $1.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026